Massachusetts-based Cytiva, a provider of technologies that advance the development and manufacture of therapeutics, has announced plans to open a new factory in Cardiff, Wales, UK. The new 11,000m2 facility is part of a wider two-year $1.5bn global expansion plan.
The company has commenced hiring for 250 positions at the plant, which will focus on the manufacture of single-use bioprocessing technologies used to make vaccines and biopharmaceuticals. Shipments from the new facility are expected to commence in 2022 with five additional clean rooms also scheduled for construction.
Mary Blenn, vice-president of global supply chains at Cytiva, commented in a company press release: “Since 2020, we have invested and significantly increased global capacity to address our customers’ growing needs. We continue to expand with new manufacturing sites, such as that in Cardiff. This facility also gives us an enhanced presence in the UK, allowing us to provide more regional options to our customers there.”
Cytiva was founded in 1968 and is headquartered in Marlborough, Massachusetts, US. It currently operates from 11 facilities across Asia, Europe and the US.
